Evoke Pharma, Inc. (EVOK)
Market Cap | 10.48M |
Revenue (ttm) | 8.62M |
Net Income (ttm) | -6.15M |
Shares Out | 2.07M |
EPS (ttm) | -4.17 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 53,206 |
Open | 5.07 |
Previous Close | 5.49 |
Day's Range | 4.81 - 5.38 |
52-Week Range | 3.54 - 14.04 |
Beta | 0.16 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Nov 7, 2024 |
About EVOK
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beac... [Read more]
Financial Performance
In 2023, Evoke Pharma's revenue was $5.18 million, an increase of 106.51% compared to the previous year's $2.51 million. Losses were -$7.79 million, -5.25% less than in 2022.
Financial StatementsNews
Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical offi...
Evoke Pharma Receives Notices of Allowance for Two Additional US Patent Applications Protecting GIMOTI®
SOLANA BEACH, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...
InvestCloud to Partner with Evoke Advisors to Transform Their Digital Experience
LOS ANGELES--(BUSINESS WIRE)--InvestCloud, a global leader in wealth technology, announced a strategic partnership with Registered Investment Adviser (RIA) Evoke Advisors (Evoke) to transform their di...
Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
GIMOTI third quarter net product sales of $2.7 million, highest quarterly revenue ever with a 70% increase year-over-year
Evoke Pharma stock surges over 100%—here's why
Evoke Pharma Inc (NASDAQ: EVOK) opened well over 100% up on Monday after reporting positive results for a study on its metoclopramide nasal spray. The pharmaceutical company said its nasal spray kno...
Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
SOLANA BEACH, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...
Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
SOLANA BEACH, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...
Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
Nantahala to nominate 2 board seats Portion of the proceeds received from warrants executed at $8.16/share SOLANA BEACH, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a ...
Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis Gimoti remains the sole proprietary FDA approved treatment for symptoms of diabetic gastroparesis
XLR8 America and EVoke Systems Partner to Deliver Smarter EV Charging Stations to the Parking Industry
SAN DIEGO--(BUSINESS WIRE)-- #CleanTech--EVoke Partnership.
Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
SOLANA BEACH, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...
Evoke Pharma to Present at H.C. Wainwright's 26th Annual Global Investment Conference
SOLANA BEACH, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...
Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million
Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
Collaborating with advocacy groups to amplify gastroparesis awareness for millions of patients worldwide Call for action to improve health and access for patients SOLANA BEACH, Calif., Aug. 08, 2024 (...
Evoke Pharma, Inc. Announces Reverse Stock Split
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK) , a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...
Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
Expanded State Medicaid Access for GIMOTI Achieved highest ever monthly GIMOTI prescription fills in May 2024 Promoted former VP of Finance, Mark Kowieski to Chief Financial Officer SOLANA BEACH, Cali...
Evoke Pharma to Present Additional GIMOTI Healthcare Utilization Data Focused on Gastroparesis Care Insights in Women at 2024 Digestive Disease Week (DDW) Conference
SOLANA BEACH, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...
Evoke Pharma Reports First Quarter 2024 Financial Results
114% year-over-year increase in net product sales 70% prescriber growth in Q1 2024 compared to Q4 2023 Growing sales metrics reaffirms company's $14M net revenue guidance for 2024
Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present Michael Cline, DO., Medical Director Gastroparesis Clinic, Cleveland Clinic to present
Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D'Onofrio to Chief Executive Officer
SOLANA BEACH, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with a...
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript
Evoke Pharma, Inc. (EVOK) Q4 2023 Earnings Call Transcript
Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Fiscal year 2023 net product sales from prescriptions totaled approximately $5.2M, a 107% increase from 2022
Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
SOLANA BEACH, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases with an emphasis...
Evoke Pharma Announces Closing of $7.5 Million Public Offering
Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full Potential for Additional $22.5 Million in the Event of Exercise of Common Warrants in Full
Evoke Pharma Announces Pricing of Underwritten Public Offering of up to $30 Million
SOLANA BEACH, Calif., Feb. 09, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an...